Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare and Seattle Genetics agree cancer alliance

Bayer HealthCare and Seattle Genetics agree cancer alliance

27th June 2013

Bayer HealthCare has entered into a new antibody-drug conjugate (ADC) collaboration with Seattle Genetics that will result in the creation of new cancer therapies.

The agreement will grant Bayer HealthCare worldwide rights to utilise Seattle Genetics' auristatin-based ADC technology as the basis for research into several oncology targets.

Seattle Genetics' proprietary technology employs synthetic cytotoxic agents and stable linker systems to attach cytotoxic agents to antibodies, enhancing anti-tumour activity while reducing many of the harmful effects of traditional chemotherapy.

Bayer will be responsible for research, product development, manufacturing and commercialisation of all products created under the terms of the agreement.

Professor Andreas Busch, member of the Bayer HealthCare executive committee and head of global drug discovery, said: "Antibody-drug conjugates are one of our focus areas in oncology research and we are looking forward to strengthening our portfolio in this area of personalised medicine."

This comes after Bayer HealthCare entered into a long-term strategic partnership with contract research organisation CRS earlier this month.ADNFCR-8000103-ID-801604814-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.